ATXN7L3B

Across TCGA pan-cancer cohorts, ATXN7L3B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATXN7L3B data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATXN7L3B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATXN7L3B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where ATXN7L3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.985	0.172	.024	8	view →
UCEC	OS	Quartile	All	0.871	1.000	.047	4	view →
LSCC	DFS	Median	All	0.806	0.628	.037	3	view →
LUAD	OS	Quartile	III,IV	0.957	0.592	.040	3	view →
HNSC	DFS	Tertile	II,III,IV	1.000	0.943	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATXN7L3B–CCRCC (DFS)

Open the CCRCC breakdown →